PFS
FIG 2. · Panel A
Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
James Chih-Hsin Yang, Dae Ho Lee, Jong-Seok Lee, Yun Fan, Filippo de Marinis, Eiji Iwama, Takako Inoue, Jerónimo Rodríguez-Cid, Li Zhang, Cheng-Ta Yang, Emmanuel de la Mora Jimenez, Jianying Zhou, Maurice Pérol, Ki Hyeong Lee, David Vicente, Eiki Ichihara, Gregory J Riely, Yiwen Luo, Diana Chirovsky, M Catherine Pietanza, Niyati Bhagwati, Shun Lu
J Clin Oncol 42(34) 4029-4039
PURPOSE: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard first-line therapy for EGFR-mutant, metastatic non-small cell lung cancer (NSCLC); however, most patients experience disease progression. We report results from the randomized, double-blind, phase III KEYNOTE-789 study of pemetrexed and platinum-based chemotherapy with or without pembrolizumab for TKI-resistant, EGFR-mutant, metastatic nonsquamous NSCLC (ClinicalTrials.gov identifier: NCT03515837). METHODS: Adults with pathologically confirmed stage IV nonsquamous NSCLC, documented DEL19 or L858R EGFR mutation, and progression after EGFR-TKI treatment were randomly assigned 1:1 to 35 cycles of pembrolizumab 200 mg or placebo once every 3 weeks plus four cycles of pemetrexed and carboplatin or cisplatin once every 3 weeks and then maintenance pemetrexed. Dual primary end points were progression-free survival (PFS) and overall survival (OS). Final PFS testing was completed at the second interim analysis (IA2; data cutoff, December 3, 2021); OS was tested at final analysis (FA; data cutoff, January 17, 2023). Efficacy boundaries were one-sided P = .0117 for PFS and OS. RESULTS: Four hundred ninety-two patients were randomly assigned to pembrolizumab plus chemotherapy (n = 245) or placebo plus chemotherapy (n = 247). At IA2, the median PFS was 5.6 months for pembrolizumab plus chemotherapy versus 5.5 months for placebo plus chemotherapy (hazard ratio [HR], 0.80 [95% CI, 0.65 to 0.97]; P = .0122). At FA, the median OS was 15.9 versus 14.7 months, respectively (HR, 0.84 [95% CI, 0.69 to 1.02]; P = .0362). Grade ≥3 treatment-related adverse events occurred in 43.7% of pembrolizumab plus chemotherapy recipients versus 38.6% of placebo plus chemotherapy recipients. CONCLUSION: Addition of pembrolizumab to chemotherapy in patients with TKI-resistant, EGFR-mutant, metastatic nonsquamous NSCLC did not significantly prolong PFS or OS versus placebo plus chemotherapy in KEYNOTE-789.
4 个 Figure · 11 个 KM 面板
FIG 2. PFS and OS. (A) Kaplan-Meier estimates of PFS tested at IA2 according to RECIST version 1.1 by blinded independent central review. (B) Analysis of PFS in key subgroups. (C) Kaplan-Meier estimates of OS tested at protocol-specified final analysis. (D) Analysis of OS in key subgroups. a For the overall population, analysis was based on the Cox regression model with treatment as a covariate stratified by PD-L1 TPS (≥50% or <50%), treatment history (osimertinib or no osimertinib), and geographic region (East Asia or not East Asia). For subgroups, analysis was based on the unstratified Cox regression model with treatment as a covariate. ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR , epidermal growth factor receptor; HR, hazard ratio; IA2, second interim analysis; OS, overall survival; PFS, progression-free survival; TKI, tyrosine kinase inhibitor; TPS, tumor proportion score.
FIG 2. · Panel A
Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 2. · Panel C
Panel C 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 3. Kaplan-Meier analysis of PFS at IA2 and OS at protocol-specified FA by PD-L1 TPS. (A) PFS in patients with PD-L1 TPS ≥1%. (B) PFS in patients with PD-L1 TPS < 1%. (C) OS in patients with PD-L1 TPS ≥1%. (D) OS in patients with PD-L1 TPS < 1%. FA, final analysis; HR, hazard ratio; IA2, second interim analysis; OS, overall survival; PFS, progression-free survival; TPS, tumor proportion score.
FIG 3. · Panel A
Panel A 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 3. · Panel B
Panel B 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 3. · Panel C
Panel C 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 3. · Panel D
Panel D 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG 4. Kaplan-Meier estimate of time to true deterioration for the composite end point of cough, chest pain, and dyspnea at the protocol-specified final analysis. HR, hazard ratio; NR, not reached.
FIG 4. · Panel time_to_deterioration
Panel time_to_deterioration 是同一 FIG 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG A2. Kaplan-Meier analysis of progression-free survival per RECIST version 1.1 by BICR at IA2 and OS at the final analysis in PD-L1 TPS subgroups. (A) PFS in patients with PD-L1 TPS 1%-49%. (B) PFS in patients with PD-L1 TPS ≥50%. (C) OS in patients with PD-L1 1%-49%. (D) OS in patients with PD-L1 TPS ≥50%. BICR, blinded independent central review; HR, hazard ratio; IA2, second interim analysis; OS, overall survival; PFS, progression-free survival; TPS, tumor proportion score.
FIG A2. · Panel A
Panel A 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG A2. · Panel B
Panel B 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG A2. · Panel C
Panel C 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIG A2. · Panel D
Panel D 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。